Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2456302 Receptor Occupancy in Healthy Volunteers (KOR1)
NCT02218775Phase 1Withdrawn
- Start
- Oct 2014
- Primary completion
- Apr 2015
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aticaprant in anxiety disorder, mood disorder and anhedonia ((none)). Primary endpoints: Kappa Opioid Receptor Occupancy at Day 16, Mu Opioid Receptor Occupancy at Day 16 and 1 more. Planned start Oct 2014; status: withdrawn.
02
Drugs
aticaprant
03
Conditions
anxiety disordermood disorderanhedonia ((none))
Beyond the preview
Go deeper on NCT02218775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218775.